Lipid Metabolism Disorders
Methodology & AI Transparency ⓘ
Lipid Metabolism Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Metabolism is the process your body uses to make energy from the food you eat.
- 2 Real-world patient consensus: Mapped to Cholesterol, Triglycerides & Lipids under ICD-10-CM E78.4 for Lipid Metabolism Disorders clinical workups.
- 3 Typical cash cost range: Primary evaluation for Lipid Metabolism Disorders incorporates ApoB quantification [Lipid Metabolism Disorders E78.4] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Lipid Metabolism Disorders: maintaining Fasting Triglycerides [Lipid Metabolism Disorders E78.4] within < 100 mg/dL (E78.4).
Ask our AI Specialists anything about Lipid Metabolism Disorders
What Is Lipid Metabolism Disorders?
Metabolism is the process your body uses to make energy from the food you eat. Food is made up of proteins, carbohydrates, and fats. Chemicals in your digestive system (enzymes) break the food parts down into sugars and acids, your body's fuel. Your body can use this fuel right away, or it can store the energy in your body tissues. If you have a metabolic disorder , something goes wrong with this process. Lipid metabolism disorders, such as Gaucher disease and Tay-Sachs disease , involve lipids. Lipids are fats or fat-like substances. They include oils, fatty acids, waxes, and cholesterol.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Lipid Metabolism Disorders (code E78.4) is impaired hepatic LDL-receptor in Lipid Metabolism Disorders (E78.4: clearance), Cross-referenced with NIH MeSH (Lipid Metabolism, Inborn Errors, Lipid Metabolism Disorders), which Cholesterol, Triglycerides & Lipids clinicians address while surveilling Fasting Triglycerides [Lipid Metabolism Disorders E78.4] (< 100 mg/dL (E78.4)).
Common Symptoms & Clinical Signs
- • Presentation of Lipid Metabolism Disorders (E78.4): coronary artery calcium [Lipid Metabolism Disorders E78.4]
- • Secondary Lipid Metabolism Disorders clinical sign: silent elevation of in Lipid Metabolism Disorders (E78.4: LDL-C, ApoB100, or)
- • Symptom flares in Lipid Metabolism Disorders correlating with Fasting Triglycerides [Lipid Metabolism Disorders E78.4] deviation outside < 100 mg/dL (E78.4)
- • Functional cholesterol & lipids impact requiring ApoB quantification [Lipid Metabolism Disorders E78.4] evaluation (E78.4)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Lipid Metabolism Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E78.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cholesterol, Triglycerides & Lipids | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Triglycerides [Lipid Metabolism Disorders E78.4] | < 100 mg/dL (E78.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Lipoprotein(a) [Lp(a)] [Lipid Metabolism Disorders E78.4] | < 75 nmol/L (E78.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Lipid Metabolism Disorders E78.4] | < 70 mg/dL (< 55 mg/dL high risk) (E78.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Lipid Metabolism Disorders
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nutrilipid I.V. Fat Emulsion (Soybean Oil) Nutrilipid I.V. Fat Emulsion • RxCUI RXN-B02644460 | Lipid Emulsion | 79% | $2.2600 | $ 171.22 /mo |
| Intralipid (I.V. Fat Emulsion) Intralipid • RxCUI 805131 | Lipid Emulsion | 86% | $1.2800 | $ 100.66 /mo |
| Niacin Niacor • RxCUI 1098134 | Nicotinic Acid | 88% | $0.1492 | $ 14.54 /mo |
| Ezetimibe and Simvastatin Vytorin • RxCUI 476345 | HMG-CoA Reductase Inhibitor | 74% | $0.2726 | $ 19.54 /mo |
| Smoflipid Smoflipid Generic • RxCUI RXN-63323820-2550 | Lipid Emulsion | 82% | $1.2800 | $ 60.34 /mo |
| Soybean Oil Nutrilipid I.V. Fat Emulsion • RxCUI RXN-02644460-2673 | Lipid Emulsion | 80% | $0.9500 | $ 46.98 /mo |
| Atorvastatin Calcium, Film Coated Atorvastatin Calcium, Film Coated Generic • RxCUI 617311 | HMG-CoA Reductase Inhibitor | 94% | $0.0276 | $ 9.62 /mo |
| Clinolipid (Olive Oil and Soybean Oil) Clinolipid • RxCUI 1986373 | Lipid Emulsion | 89% | $0.5500 | $ 48.10 /mo |
| Simvastatin Zocor • RxCUI 314231 | HMG-CoA Reductase Inhibitor | 92% | $0.0278 | $ 5.34 /mo |
| Fluvastatin Lescol • RxCUI 310405 | HMG-CoA Reductase Inhibitor | 76% | $2.8581 | $ 52.79 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lipid Metabolism Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Major outcomes in high-risk hypertensive patients randomized to: What a 9,048-Participant Study Found Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. JAMA • 2002-12-18 • Randomized Controlled Trial | N = 9,048 | 96/100 | PMID 12479763 ↗ |
| New Insights on Benefits and safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed high: What a 1,148-Participant Study Found The significant reductions of atherogenic lipids including LDL-C, non-HDL-C, and apolipoprotein B seen with evolocumab are similar in patients with and without mixed high cholesterol. Cardiovascular drugs and therapy • 2016-06-15 • Phase III Randomized Trial | N = 1,148 | 96/100 | PMID 27240673 ↗ |
| New Insights on Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus: What a 2,959-Participant Study Found Ezetimibe/simvastatin was more effective than rosuvastatin in LDL-C lowering, and provided greater or comparable improvements in other lipid measures and hsCRP at the approved usual starting, next highest, and maximum doses in... Current medical research and opinion • 2006-10-15 • Randomized Controlled Trial | N = 2,959 | 96/100 | PMID 17022864 ↗ |
| New Insights on Glycolipid and Hormonal Profiles in Young Men with Early-Onset Androgenetic hair: What a 1,009-Participant Study Found The acknowledgement of this syndrome would be of importance to prevent the long-term consequences on health in the affected men. Scientific reports • 2017-08-10 • Meta-Analysis | N = 1,009 | 94/100 | PMID 28798373 ↗ |
| New Insights on Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and: What a 263-Participant Study Found Approximately 45% of. International journal of clinical practice • 2010-07-15 • Randomized Controlled Trial | N = 263 | 93/100 | PMID 20487050 ↗ |
Lipid Metabolism Disorders Patient Community & “People Like Me” Threads
Filter Lipid Metabolism Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.